<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319711409742</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319711409742</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Coronary Heart Disease</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Role of Macrophage Colony-Stimulating Factor in Patients With Acute Myocardial Infarction</article-title>
<subtitle>A Pilot Study</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Novo</surname>
<given-names>Giuseppina</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0003319711409742">1</xref>
<xref ref-type="corresp" rid="corresp1-0003319711409742"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rizzo</surname>
<given-names>Manfredi</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0003319711409742">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carruba</surname>
<given-names>Salvatore La</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0003319711409742">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Caruso</surname>
<given-names>Marco</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711409742">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Amoroso</surname>
<given-names>Gisella Rita</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711409742">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Balistreri</surname>
<given-names>Carmela Rita</given-names>
</name>
<degrees>SciD</degrees>
<xref ref-type="aff" rid="aff3-0003319711409742">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Coppola</surname>
<given-names>Giuseppe</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711409742">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Evola</surname>
<given-names>Giovanna</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711409742">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Caruso</surname>
<given-names>Calogero</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-0003319711409742">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Assennato</surname>
<given-names>Pasquale</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711409742">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Novo</surname>
<given-names>Salvatore</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711409742">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mancuso</surname>
<given-names>Dario</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff4-0003319711409742">4</xref>
</contrib>
</contrib-group>
<aff id="aff1-0003319711409742"><label>1</label>Department of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy</aff>
<aff id="aff2-0003319711409742"><label>2</label>Division of Internal Medicine, Villa Sofia Whitaker Hospital, Palermo, Italy</aff>
<aff id="aff3-0003319711409742"><label>3</label>Department of Pathobiology and Biomedical Methodologies, University of Palermo, Palermo, Italy</aff>
<aff id="aff4-0003319711409742"><label>4</label>Chair and Division of Cardiology, Department of Internal Medicine and Cardiovascular Diseases, University of Palermo, Italy.</aff>
<author-notes>
<corresp id="corresp1-0003319711409742">Giuseppina Novo, Department of Internal Medicine and Medical Specialties, University of Palermo, Via del Vespro 129, 90100, Palermo, Italy Email:<email>novog@unipa.it</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>63</volume>
<issue>2</issue>
<fpage>127</fpage>
<lpage>130</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>We assessed whether macrophage colony-stimulating factor (M-CSF) levels are associated with left ventricular systolic dysfunction (LVSD) in patients with acute myocardial infarction (AMI). We studied 56 patients with AMI (mean age: 67 ± 12 years) and identified those with clinical (Killip class &gt;II) or echocardiographic signs (ejection fraction ≤45%) of LVSD. We evaluated the established cardiovascular risk factors and measured several cardiovascular biomarkers, including M-CSF. Serum M-CSF concentrations (pg/mL) were significantly increased in patients with both clinical and echocardiographic signs of LVSD (460 ± 265 vs 290 ± 210, <italic>P</italic> = .0103 and 493 ± 299 vs 287 ± 174, <italic>P</italic> = .0028, respectively). We found a significant inverse association between M-CSF and ejection fraction (<italic>r</italic> = −.351, <italic>P</italic> = .0079). Logistic regression analysis revealed that, among all evaluated clinical and biochemical parameters, the stronger predictor of LVSD was M-CSF (odds ratios 2.1, 95% confidence interval 1.1-2.9, <italic>P</italic> = .0168). This is the first study reporting plasma M-CSF levels as independent determinants of low LV ejection fraction and clinical LV dysfunction in patients with AMI.</p>
</abstract>
<kwd-group>
<kwd>macrophage colony-stimulating factor</kwd>
<kwd>myocardial infarction</kwd>
<kwd>heart failure</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0003319711409742">
<title>Background</title>
<p>Clinical and basic medical research has demonstrated that atherosclerosis is an inflammatory disease; inflammation also plays a role in the development of acute coronary syndromes (ACS).<sup><xref ref-type="bibr" rid="bibr1-0003319711409742">1</xref></sup> Several studies have demonstrated the importance of fibrinogen and C-reactive protein as risk markers.<sup><xref ref-type="bibr" rid="bibr2-0003319711409742">2</xref><xref ref-type="bibr" rid="bibr3-0003319711409742"/>–<xref ref-type="bibr" rid="bibr4-0003319711409742">4</xref></sup> Other biochemical markers include CD40 ligand, myeloperoxidase, monocyte chemoattractant protein 1, interleukin (IL) 1, IL-6, IL-18, and tumour necrosis factor, which are increased in patients with ACS; further, these markers seem to be able to identify subgroups of patients at higher cardiac risk, even among those with negative cardiac troponin.<sup><xref ref-type="bibr" rid="bibr5-0003319711409742">5</xref><xref ref-type="bibr" rid="bibr6-0003319711409742"/><xref ref-type="bibr" rid="bibr7-0003319711409742"/>–<xref ref-type="bibr" rid="bibr8-0003319711409742">8</xref></sup> Despite scientific evidence, the practical use and the peculiar role of these biomarkers during ACS for diagnostic, therapeutic, and follow-up strategies remain uncertain.<sup><xref ref-type="bibr" rid="bibr5-0003319711409742">5</xref></sup></p>
</sec>
<sec id="section2-0003319711409742">
<title>Aims</title>
<p>Macrophage colony-stimulating factor (M-CSF) is a growth factor involved in the proliferation and differentiation of macrophages, cells with a role in plaque genesis and destabilization.<sup><xref ref-type="bibr" rid="bibr5-0003319711409742">5</xref></sup> We determined whether M-CSF serum levels, as measured during acute myocardial infarction (AMI), may be a useful marker to predict left ventricular systolic dysfunction (LVSD). We also assessed the relationships between M-CSF and the N-terminal fragment of pro-B-type natriuretic peptide (Nt-pro-BNP), a marker of LVSD.<sup><xref ref-type="bibr" rid="bibr5-0003319711409742">5</xref></sup></p>
</sec>
<sec id="section3-0003319711409742">
<title>Methods</title>
<p>We studied 56 patients (mean age: 67 ± 12 years), consecutively admitted to the Intensive Coronary Care Unit of our University Hospital for AMI (either ST elevation myocardial infarction [STEMI] or non-ST elevation myocardial infarction [NSTEMI]). Acute MI was defined according to the Joint European Society of Cardiology (ESC)/American College of Cardiology Foundation (ACCF)/American Heart Association (AHA), World Heart Federation (WHF) guidelines.<sup><xref ref-type="bibr" rid="bibr9-0003319711409742">9</xref></sup> Patients underwent medical examination, biochemical analysis and echocardiography (Siemens Sequoia machine, Siemens, Malvern, PA, USA), and the ejection fraction was quantified by biplane Simpson method.<sup><xref ref-type="bibr" rid="bibr10-0003319711409742">10</xref></sup> The adopted procedures were in agreement with the Helsinki Declaration of 1975 as revised in 1983.<sup><xref ref-type="bibr" rid="bibr11-0003319711409742">11</xref></sup> All participants gave their informed consent to participate in the study. At admission, they answered a questionnaire on personal and medical characteristics, including age, past medical history, and medication. Among the main cardiovascular risk factors, the presence of family history of coronary heart disease ([CHD] in a first-degree relative before 55 years), hypertension (systolic or diastolic blood pressure ≥140 or ≥90 mm Hg, respectively, or pharmacological therapy with antihypertensive drugs), diabetes (fasting glucose plasma concentrations higher than 126 mg/dL or pharmacological therapy with antidiabetic drugs or insulin), dylipidemia (plasma triglycerides &gt;150 mg/dL and/or plasma low-density lipoprotein cholesterol [LDL-C] &gt;130 mg/dL and/or plasma high-density lipoprotein cholesterol [HDL-C] &lt;40 mg/dL in men and &lt;50 mg/dL in women, or pharmacological therapy with lipid-lowering drugs), and current smoking were considered. Height and weight were recorded and body mass index (BMI) was expressed as kg/m<sup>2</sup>. Participants were categorized as having obesity if the BMI was ≥30 kg/m<sup>2</sup>. Further, the Killip class was determined, and we identified patients with clinical (Killip class &gt;2) or echocardiographic signs (ejection fraction &lt;45%) of LVSD.</p>
<p>Within 24 hours of admission, a venous blood sample was drawn for the determination of M-CSF (human MCSF; Quantikinine R&amp;D system, Minneapolis, Minnesota), high-sensitivity C-reactive protein ([hsCRP] high-sensitivity ELISA kit, IBL, Hamburg, Germany), fibrinogen (according to the coagulative method of Von Clauss<sup><xref ref-type="bibr" rid="bibr3-0003319711409742">3</xref></sup>), and the Nt-pro-BNP (immunoassay Elecsys; Roche Diagnostics, Basel, Switzerland).</p>
<p>Statistical analysis was performed using the Statview Program 5.0 (SAS Institute Inc., Cary, North Carolina). Differences in the investigated parameters among study groups were assessed by the unpaired Student <italic>t</italic> test (for numeric variables) and by the χ<sup>2</sup> test (for nominal variables). Correlation analysis was performed using the Spearman rank correlation method. Multivariate analysis (by logistic regression) was performed in order to assess the potential independent associations of the studied variables with LVSD; in the model we included all the investigated clinical and laboratory parameters.</p>
</sec>
<sec id="section4-0003319711409742">
<title>Results</title>
<p>As shown in<xref ref-type="table" rid="table1-0003319711409742">Table 1</xref>, patients with echocardiographic signs of LVSD (eg, those with ejection fraction ≤45%) had lower prevalence of current smokers (<italic>P</italic> = .0163), with higher prevalence of diabetes (<italic>P</italic> = .0341) and dyslipidemia (<italic>P</italic> = .0441), as well as increased concentrations of M-CSF (<italic>P</italic> = .0103) and fibrinogen (<italic>P</italic> = .0215). When we considered the classification according to the Killip classes (data not shown), patients with clinical signs of LVSD (eg, with Killip class ≥2, n = 17) had increased concentrations of M-CSF (493 ± 299 vs 287 ± 174 pg/mL, <italic>P</italic> = .0028).</p>
<table-wrap id="table1-0003319711409742" position="float">
<label>Table 1.</label>
<caption>
<p>Univariate and Multivariate Analyses of Clinical and Biochemical Parameters in Relation to the Presence of Left Ventricular Systolic Dysfunction (eg, With Ejection Fraction ≤45%)</p>
</caption>
<graphic alternate-form-of="table1-0003319711409742" xlink:href="10.1177_0003319711409742-table1.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th align="center">With Ejection Fraction &gt;45% (n = 35)</th>
<th align="center"><italic>P</italic></th>
<th align="center">With Ejection Fraction ≤45% (n = 21)</th>
<th align="center">Logistic Regression Analysis Odds Ratios (95% CI), <italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>65 ± 12</td>
<td>. 1664</td>
<td>69 ± 10</td>
<td>0.9 (0.9-1.0), .1665</td>
</tr>
<tr>
<td>Men, n (%)</td>
<td>19 (54)</td>
<td>. 3619</td>
<td>14 (67)</td>
<td>0.6 (0.2-1.8), .3637</td>
</tr>
<tr>
<td>Family history of CVD, n (%)</td>
<td>18 (51)</td>
<td>. 3328</td>
<td>8 (38)</td>
<td>1.7 (0.6-5.2), .3346</td>
</tr>
<tr>
<td>Obesity, n (%)</td>
<td>10 (29)</td>
<td>. 4600</td>
<td>8 (38)</td>
<td>0.7 (0.2-2.0), .4613</td>
</tr>
<tr>
<td>Current smokers, n (%)</td>
<td>18 (51)</td>
<td>
<bold>. 0163</bold>
</td>
<td>4 (19)</td>
<td>0.5 (0.3-0.6), .4208</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>26 (74)</td>
<td>. 3293</td>
<td>13 (62)</td>
<td>1.8 (0.6-5.7), .3318</td>
</tr>
<tr>
<td>Diabetes, n (%)</td>
<td>10 (29)</td>
<td>
<bold>. 0341</bold>
</td>
<td>12 (57)</td>
<td>1.3 (1.2-1.9),<bold>. 0374</bold>
</td>
</tr>
<tr>
<td>Dyslipidemia, n (%)</td>
<td>12 (34)</td>
<td>
<bold>. 0441</bold>
</td>
<td>13 (62)</td>
<td>1.3 (1.1-2.0),<bold>. 0475</bold>
</td>
</tr>
<tr>
<td>STEMI (%)</td>
<td>10 (29)</td>
<td>. 4600</td>
<td>8 (38)</td>
<td>0.7 (0.2-2.0), .4613</td>
</tr>
<tr>
<td>Multivessel disease (%)</td>
<td>16 (46)</td>
<td>. 4076</td>
<td>12 (57)</td>
<td>0.6 (0.2-1.9), .4089</td>
</tr>
<tr>
<td>M-CSF (pg/mL)</td>
<td>290 ± 210</td>
<td>
<bold>. 0103</bold>
</td>
<td>460 ± 265</td>
<td>2.1 (1.1-2.9),<bold>. 0168</bold>
</td>
</tr>
<tr>
<td>Nt-pro-BNP (pg/mL)</td>
<td>4096 ± 6820</td>
<td>. 1127</td>
<td>8590 ± 11192</td>
<td>1.0 (1.0-1.1), .1453</td>
</tr>
<tr>
<td>C-reactive protein (mg/L)</td>
<td>1.0 ± 0.5</td>
<td>. 4080</td>
<td>1.0 ± 0.4</td>
<td>0.9 (0.9-1.0), .4009</td>
</tr>
<tr>
<td>Fibrinogen (mg/dL)</td>
<td>416 ± 96</td>
<td>
<bold>. 0215</bold>
</td>
<td>495 ± 113</td>
<td>1.3 (1.1-1.8),<bold>. 0295</bold>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0003319711409742">
<p>Abbreviations: CV, cardiovascular diseases; Nt-pro-BNP, N-terminal fragment of pro-B-type natriuretic peptide; M-CSF, macrophage colony-stimulating factor.</p>
</fn>
<fn id="table-fn2-0003319711409742">
<p><sup>a</sup> Values are indicated in percentages or as mean ± SD. The boldface <italic>P</italic> values indicate the reached statistical significance.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Spearman correlation analysis was performed to assess the associations between left ventricular systolic function (as measured by ejection fraction) and clinical and biochemical parameters. We did not find any significant correlation with age, hsCRP, and fibrinogen (data not shown); while we found inverse correlations with Nt-pro-BNP (<italic>r</italic> = −.424, <italic>P</italic> = .0051, data not shown) and M-CSF (<italic>r</italic> = −.351, <italic>P</italic> = .0079; see<xref ref-type="fig" rid="fig1-0003319711409742">Figure 1</xref>). Further (data not shown), we found significant positive correlations between M-CSF and Nt-proBNP (<italic>r</italic> = .498, <italic>P</italic> = .0008), hsCRP (<italic>r</italic> = .364, <italic>P</italic> = .0063) as well as fibrinogen (<italic>r</italic> = .340, <italic>P</italic> = .0256).</p>
<fig id="fig1-0003319711409742" position="float">
<label>Figure 1.</label>
<caption>
<p>Spearman correlation between left ventricular systolic function (percentage of ejection fraction [EF]) and macrophage colony-stimulating plasma levels ([M-CSF] in pg/mL); <italic>r</italic> = −.351; <italic>P</italic> = .0079.</p>
</caption>
<graphic xlink:href="10.1177_0003319711409742-fig1.tif"/>
</fig>
<p>We further investigated by logistic regression analysis (<xref ref-type="table" rid="table1-0003319711409742">Table 1</xref>) potential variables independently associated with LVSD in a model that included all the investigated clinical and biochemical parameters; we found a predictive role (odds ratios [ORs]; 95% confidence intervals [CIs]) for M-CSF (OR 2.1, CI 1.1-2.9, <italic>P</italic> = .0168), diabetes (OR 1.3, CI 1.2-1.9, <italic>P</italic> = .0374), dyslipidemia (OR 1.3, CI 1.1-2.0, <italic>P</italic> = .0475), and fibrinogen (OR 1.1, CI 1.1-1.8, <italic>P</italic> = .0295).</p>
</sec>
<sec id="section5-0003319711409742">
<title>Conclusions</title>
<p>Previous studies showed increased M-CSF levels in patients with stable and unstable angina.<sup><xref ref-type="bibr" rid="bibr7-0003319711409742">7</xref>,<xref ref-type="bibr" rid="bibr8-0003319711409742">8</xref>,<xref ref-type="bibr" rid="bibr12-0003319711409742">12</xref></sup> This is the first study that has shown the association between M-CSF levels and LVSD in patients with AMI. The reliability of M-CSF as marker of left ventricular dysfunction in our patients is also addressed by its correlation with Nt-pro-BNP, a well-established marker of LVSD. At present, we can only speculate about the mechanisms involved. Excessive infiltration of inflammatory cells into the injured myocardium may cause an imbalance between synthesis and degradation of extracellular matrix, resulting in adverse postmyocardial infarction remodeling and consequently LVSD.<sup><xref ref-type="bibr" rid="bibr13-0003319711409742">13</xref></sup> It has been suggested that this process may result in infarct size expansion and left ventricular remodeling after AMI<sup><xref ref-type="bibr" rid="bibr14-0003319711409742">14</xref></sup>; another study showed M-CSF treatment attenuated deterioration of left ventricular function after AMI by accelerating infarct repair.<sup><xref ref-type="bibr" rid="bibr15-0003319711409742">15</xref></sup>
</p>
<p>In this context, measurement of M-CSF seems to be able to provide information adjunctive to inflammatory markers and Nt-pro-BNP, and it therefore may represent a novel and intriguing prognostic marker in patients with AMI. Interestingly, we have found significant correlations between M-CSF and fibrinogen as well as hsCRP. Indeed, M-CSF may provide information not only regarding the inflammatory burden and consequently the tendency to adverse events but also the likelihood of developing heart failure. Therefore, the present study extends existing data on the activation of M-CSF in left ventricular systolic dysfunction.<sup><xref ref-type="bibr" rid="bibr14-0003319711409742">14</xref>,<xref ref-type="bibr" rid="bibr16-0003319711409742">16</xref></sup>
</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="other" id="fn1-0003319711409742">
<p>The authors Giuseppina Novo and Manfredi Rizzo contributed equally to the present work.</p>
</fn>
<fn fn-type="conflict" id="fn2-0003319711409742">
<p>The author(s) declared no conflicts of interest with respect to the authorship and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn3-0003319711409742">
<p>The author(s) received no financial support for the research and/or authorship of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319711409742">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Libby</surname>
<given-names>P.</given-names>
</name>
</person-group> <article-title>Current concepts of the pathogenesis of the acute coronary syndromes</article-title>. <source>Circulation</source>. <year>2001</year>;<volume>104</volume>(<issue>3</issue>):<fpage>365</fpage>.</citation>
</ref>
<ref id="bibr2-0003319711409742">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morrow</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Rifai</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Antman</surname>
<given-names>EM</given-names>
</name>
<etal/>
</person-group>. <article-title>C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy</article-title>. <source>J Am Coll Cardiol</source>. <year>1998</year>;<volume>31</volume>(<issue>7</issue>):<fpage>1460</fpage>–<lpage>1465</lpage>.</citation>
</ref>
<ref id="bibr3-0003319711409742">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corrado</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rizzo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tantillo</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5 years follow-up study</article-title>. <source>Stroke</source>. <year>2006</year>;<volume>37</volume>(<issue>
</issue>):<fpage>482</fpage>–<lpage>486</lpage>.</citation>
</ref>
<ref id="bibr4-0003319711409742">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rizzo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Corrado</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Coppola</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Muratori</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Novo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Novo</surname>
<given-names>S.</given-names>
</name>
</person-group> <article-title>Prediction of cardio- and cerebro-vascular events in patients with subclinical carotid atherosclerosis and low HDL-cholesterol</article-title>. <source>Atherosclerosis</source>. <year>2008</year>;<volume>200</volume>(<issue>2</issue>):<fpage>389</fpage>–<lpage>395</lpage>.</citation>
</ref>
<ref id="bibr5-0003319711409742">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Panteghini</surname>
<given-names>M.</given-names>
</name>
</person-group> <article-title>Role and importance of biochemical markers in clinical cardiology</article-title>. <source>Euro Heart J</source>. <year>2004</year>;<volume>25</volume>(<issue>14</issue>):<fpage>1187</fpage>–<lpage>1196</lpage>.</citation>
</ref>
<ref id="bibr6-0003319711409742">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brennan</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Penn</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Van Lente</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Prognostic value of myeloperoxidase in patients with chest pain</article-title>. <source>N Engl J Med</source>. <year>2003</year>;<volume>349</volume>(<issue>17</issue>):<fpage>1595</fpage>–<lpage>1604</lpage>.</citation>
</ref>
<ref id="bibr7-0003319711409742">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moreno</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Falk</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Palacios</surname>
<given-names>IF</given-names>
</name>
<etal/>
</person-group>. <article-title>Macrophage infiltration in acute coronary syndromes: implications in plaque rupture</article-title>. <source>Circulation</source>. <year>1994</year>;<volume>90</volume>(<issue>2</issue>):<fpage>775</fpage>–<lpage>778</lpage>.</citation>
</ref>
<ref id="bibr8-0003319711409742">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ikonomidis</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Lekakis</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Revela</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Andreotti</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Nihoyannopoulos</surname>
<given-names>P.</given-names>
</name>
</person-group> <article-title>Increased circulating C reactive protein and macrophage colony stimulating factor are complementary predictors of long term outcome in patients with chronic coronary artery disease</article-title>. <source>Eur Heart J</source>. <year>2005</year>;<volume>26</volume>(<issue>16</issue>):<fpage>1618</fpage>–<lpage>1624</lpage>.</citation>
</ref>
<ref id="bibr9-0003319711409742">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thygesen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Alpert</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>White</surname>
<given-names>HD</given-names>
</name>
</person-group>.
<collab collab-type="author">Joint ESC/ACCF/AHA/WHF</collab>. <article-title>Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction</article-title>. <source>Eur Heart J</source>. <year>2007</year>;<volume>28</volume>(<issue>20</issue>):<fpage>2525</fpage>–<lpage>2538</lpage>.</citation>
</ref>
<ref id="bibr10-0003319711409742">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goerke</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Carlsson</surname>
<given-names>E.</given-names>
</name>
</person-group> <article-title>Calculation of right and left cardiac ventricular volumes</article-title>. <source>Invest Radiol</source>. <year>1967</year>;<volume>2</volume>(<issue>5</issue>):<fpage>360</fpage>.</citation>
</ref>
<ref id="bibr11-0003319711409742">
<label>11</label>
<citation citation-type="journal">
<collab collab-type="author">World Medical Association</collab> <article-title>Declaration of Helsinki: ethical principles for medical research involving human subjects</article-title>. <source>JAMA</source>. <year>2000</year>;<volume>284</volume>(<issue>23</issue>):<fpage>3043</fpage>–<lpage>3045</lpage>.</citation>
</ref>
<ref id="bibr12-0003319711409742">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoyo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ikeda</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Increased levels of monocyte derived cytokine in patients with unstable angina</article-title>. <source>Atherosclerosis</source>. <year>2002</year>;<volume>161</volume>:<fpage>403</fpage>–<lpage>408</lpage>.</citation>
</ref>
<ref id="bibr13-0003319711409742">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Postiglione</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Montagnani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ladogana</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Granulocyte macrophage-colony stimulating factor receptor expression on human cardiomyocytes from end-stage heart failure patients</article-title>. <source>Eur J Heart Fail</source>. <year>2006</year>;<volume>8</volume>(<issue>6</issue>):<fpage>564</fpage>–<lpage>570</lpage>.</citation>
</ref>
<ref id="bibr14-0003319711409742">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oren</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Erbay</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Balci</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cehreli</surname>
<given-names>S.</given-names>
</name>
</person-group> <article-title>Role of novel mediators of inflammation in left ventricular remodeling in patients with acute myocardial infarction: do they affect the outcome of patients?</article-title> <source>Angiology</source>. <year>2007</year>;<volume>58</volume>(<issue>1</issue>):<fpage>45</fpage>–<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr15-0003319711409742">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yano</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Miura</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Whittaker</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Macrophage colony-stimulating factor treatment after myocardial infarction attenuates left ventricular dysfunction by accelerating infarct repair</article-title>. <source>J Am Coll Cardiol</source>. <year>2006</year>;<volume>47</volume>(<issue>3</issue>):<fpage>626</fpage>–<lpage>634</lpage>.</citation>
</ref>
<ref id="bibr16-0003319711409742">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hohensinner</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Rychli</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zorn</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Macrophage-modulating cytokines predict adverse outcome in heart failure</article-title>. <source>Thromb Haemost</source>. <year>2010</year>;<volume>103</volume>(<issue>2</issue>):<fpage>435</fpage>–<lpage>434</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>